Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perampanel Oral Suspension in Pediatric Epilepsy
NCT01527006Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jan 2012
- Primary completion
- May 2014
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of perampanel in epilepsy, sponsored by Eisai Co., Ltd. Primary endpoints: Apparent Clearance and Steady-state Average Concentration. Started Jan 2012; status: completed.
02
Drugs
perampanel
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT01527006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01527006.